Human neutrophil targeting peptide - OrthoLogic

Drug Profile

Human neutrophil targeting peptide - OrthoLogic

Alternative Names: hNTP15; Neutrophil targeting peptide 15 - Chrysalis

Latest Information Update: 14 Jul 2008

Price : $50

At a glance

  • Originator OrthoLogic
  • Class Peptide antibiotics; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Wound infections

Most Recent Events

  • 16 Aug 2004 Chrysalis BioTechnology has been acquired by OrthoLogic
  • 02 Jul 2003 Preclinical trials in Wound infections in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top